Literature DB >> 19621427

Langerhans cell histiocytosis in a patient with stage 4 neuroblastoma receiving oral fenretinide.

Melissa Rayburg1, Alexander Towbin, Hong Yin, Todd Maugans, Barry Maurer, Rajaram Nagarajan, Brian Weiss.   

Abstract

Langerhans cell histiocytosis (LCH) has previously been reported in association with other malignancies. The pathogenesis of LCH and its relationship to other malignancies is poorly understood. We present a novel case of a child who developed an LCH bone lesion while receiving a Phase I protocol therapy with oral fenretinide/Lym-X-Sorb (4-HPR/LXS) powder for neuroblastoma.

Entities:  

Mesh：

Substances：

Year:  2009        PMID： 19621427     DOI： 10.1002/pbc.22200

Source DB:  PubMed          Journal:  Pediatr Blood Cancer        ISSN： 1545-5009            Impact factor:   3.167


  2 in total

Review 1.  Retinoic acid postconsolidation therapy for high-risk neuroblastoma patients treated with autologous haematopoietic stem cell transplantation.

Authors:  Frank Peinemann; Elvira C van Dalen; Heike Enk; Frank Berthold
Journal:  Cochrane Database Syst Rev       Date:  2017-08-25

2.  Phase I trial of fenretinide delivered orally in a novel organized lipid complex in patients with relapsed/refractory neuroblastoma: a report from the New Approaches to Neuroblastoma Therapy (NANT) consortium.

Authors:  Barry J Maurer; Min H Kang; Judith G Villablanca; Jitka Janeba; Susan Groshen; Katherine K Matthay; Paul M Sondel; John M Maris; Hollie A Jackson; Fariba Goodarzian; Hiroyuki Shimada; Scarlett Czarnecki; Beth Hasenauer; C Patrick Reynolds; Araz Marachelian
Journal:  Pediatr Blood Cancer       Date:  2013-06-29       Impact factor: 3.167
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.